The immune system operates at multiple levels — and the OSYRIS Immune category addresses three distinct ones:

KPV's research value lies in its specificity. NF-κB controls the expression of hundreds of inflammatory genes — TNF-α, IL-6, IL-8, COX-2, and many more. By preventing NF-κB nuclear translocation, KPV blocks the entire downstream inflammatory program at a single intervention point.

Receptor independence: Unlike other melanocortin-derived peptides, KPV works without activating melanocortin receptors. This makes it a cleaner tool for studying NF-κB biology without the confounding variable of receptor-mediated signaling.

Gut inflammation focus: The strongest preclinical data comes from colitis models, where KPV reduced mucosal inflammation and improved barrier function. Its small size (3 amino acids) may allow epithelial transport.

Evidence level: Solid preclinical data from multiple groups. No human trials. Smaller total evidence base than Thymosin Alpha 1.

→ KPV Research Overview

Thymosin Alpha 1 stands alone in this category — and arguably in the entire OSYRIS catalog — for the depth of its clinical evidence. Approved in 35+ countries, studied in randomized controlled trials for hepatitis B/C, investigated as a vaccine adjuvant in elderly populations. No other immune peptide has this level of human data.

Mechanism as optimization: Tα1 doesn't just "boost" immunity — it enhances the quality of immune responses. T-cell maturation, dendritic cell activation (including the IDO pathway), NK cell enhancement, and balanced cytokine modulation.

Immunosenescence relevance: The thymus — where Tα1 was discovered — involutes dramatically with age. Thymic peptide decline is a primary driver of the age-related immune deterioration that increases infection susceptibility and reduces vaccine responsiveness.

Evidence level: The strongest in the Immune category. Multiple RCTs, clinical approval in 35+ countries, decades of published data from international groups.

→ Thymosin Alpha 1 Research Overview

VIP occupies the fascinating intersection of neurology and immunology. As a neuropeptide with VPAC1/VPAC2 receptors on both neurons and immune cells, it's a natural bridge between the two systems.

Anti-inflammatory action: VIP reduces pro-inflammatory cytokines (TNF-α, IL-6, IL-12), promotes anti-inflammatory cytokine production (IL-10), and modulates the Th1/Th2 balance — a different anti-inflammatory mechanism than KPV's NF-κB inhibition.

Neuroimmune research tool: For researchers studying how the nervous system regulates immune function (and vice versa), VIP is one of the few endogenous peptides that naturally operates across both systems.

Evidence level: Extensive preclinical data from multiple international groups. Broad research profile (immune + neuro + vascular).

KLOW combines immune regulation (KPV's NF-κB inhibition) with tissue repair (BPC-157 + TB500 + GHK-Cu). This stack exists because inflammation and repair are interdependent — you can't fully understand one without the other.

The research hypothesis behind KLOW: controlling excessive inflammation (KPV) while simultaneously promoting tissue repair through three complementary mechanisms (growth factor signaling, cell migration, gene expression) produces outcomes that neither anti-inflammatory nor repair intervention achieves alone.